Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Strategy

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    Headshot of Sarah Theobald with text reading 'Healthcare communications trends in 2026'

    What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

    By Sarah Theobald

    Amiculum

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    - PMLiVE

    Does real-world use of AI in systematic literature reviews result in time and cost savings?

    By Manca Povsic and Emma Griffiths

    Amiculum

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    Genesis giveaway of a minifigure

    Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

    Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

    Genesis Research Group

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links